CICC: Maintains Outperform Rating for Junshi Biosciences (01877.HK) and Raises Target Price to 36.98 Hong Kong Dollars

According to the app of Wisdom Finance and Economics, CICC released a research report stating that considering the need for certain capital investment to advance the research and development pipeline of Junshi Biosciences (01877.HK), the profit forecast for 2025 was revised downwards from a loss of 662 million yuan to a loss of 917 million yuan, and an introduced profit forecast for 2026 was a loss of 315 million yuan. The bank maintains an outperform industry rating, as industry valuation levels rise, and the company's PD-1/VEGF, DKK1 monoclonal antibodies and other varieties of research and development are progressing positively. Based on a discounted cash flow valuation, the bank raised the target price by 101.0% to 36.98 Hong Kong dollars, representing a 21.1% upside potential from the current stock price.